PTC Therapeutics opened lower at $64.59, compared with its previous close of $64.91. In the last trading session, the stock traded between $63.40 and $64.86. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in PTC Therapeutics is now worth
$ 159.56
Giving a profit of
$ 59.56 (59.56%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 11 Analysts
Buy
90.91%
Hold
9.09%
Sell
0%
Markets Today
Today's Change
$-1.55 (-2.38%)
Day High
$64.86
Day Low
$63.40
Day Open
$64.59
Prev Close
$64.91
Volume
3,35,759
1W Return
-8.05%
1M Return
0.68%
3M Return
-14.11%
6M Return
-17.55%
1Y Return
-14.17%
Fundamentals
Market Cap ($ Mn)
5,294
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
47.70%
EPS (TTM)
$-0.62
Investment Returns
1 Week
-8.05%
1 Month
0.68%
3 Months
-14.11%
6 Months
-17.55%
9 Months
-10.66%
Financials
Quarterly
All values in $ Mn
1.2K
Mar 25
178.9
Jun 25
211.0
Sep 25
164.7
Dec 25
360.5
Jun 26
357.8
Sep 26
Updates
3Nov
Citigroup raises PTC Therapeutics price target to $109, maintains Buy
Citigroup maintains a Buy rating on PTC Therapeutics. Price target raised from $108 to $109. Analyst Eric Joseph issued the updated recommendation.
10 days ago
26Sep
PTC Therapeutics grants options and RSUs to 37 new employees
PTC Therapeutics granted 51,270 stock options and 37,995 RSUs to 37 new employees. Stock options have an exercise price of $65.96 per share, matching the Sept 22 closing price. Awards vest over four years under Nasdaq Listing Rule 5635(c)(4) inducement exception.
1mo ago
24Aug
PTC Therapeutics to present new Sephience PKU data at SSIEM 2026
PTC Therapeutics to present new Sephience data at SSIEM 2026 (Aug 25-28). AMPLIPHY study shows 100% greater Phe reduction vs sapropterin switchers. Significant dietary liberalization observed in adolescents via real-world data. Treatment achieves Phe normalization (<120 µmol/L) rapidly in responsive patients. Consistent safety profile reported across PKU spectrum including classical cases.
2mo ago
13Aug
PTC Therapeutics acquires BLA-stage Fabry program for $111M upfront
PTC Therapeutics expands its rare disease portfolio by acquiring Sangamo's ST-920 Fabry disease program for $111M upfront plus $100M in milestones. The BLA-stage asset aims for FDA submission in Q4 2026, supporting PTC's goal of cash flow break-even by 2026 without adding development costs.
3mo ago
31Jul
PTC Therapeutics Raises FY26 Sales Guidance to $1.180B-$1.280B
PTC Therapeutics upgraded its FY2026 sales guidance to $1.180 billion-$1.280 billion, surpassing the previous $1.080 billion-$1.180 billion range and the $1.196 billion market estimate.
3mo ago
20Jul
Wells Fargo maintains Overweight on PTC Therapeutics, cuts target to $93
Wells Fargo analyst Benjamin Burnett maintained an Overweight rating on PTC Therapeutics but lowered the price target to $93 from $95, indicating a modest adjustment to the stock's valuation outlook.
